moving from tirzepatide to semaglutide Switching Tirzepatide: What You Need to Know Tirzepatide vs Semaglutide for Weight
Description
Ania Jastreboff at #ADA2026 TRIUMPH-1: Phase 3 Obesity Trial with Retatrutide Retatrutide , a once-weekly triple hormone receptor agonist
No clinical evidence supports this combination
In the #US and #Europe, major expirations come later (early 2030s for semaglutide), so branded dominance continues for now, but pressure from compounding and future biosimilars is building
Third-Party Tested
In December 2024, that share had only reached 14.9%
